STOCK TITAN
  1. Home
  2. News
  3. TTOO

T2 Biosystems Inc - TTOO STOCK NEWS

Welcome to our dedicated news page for T2 Biosystems (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect T2 Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of T2 Biosystems's position in the market.

News
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
Rhea-AI Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will report financial results for Q4 and full year 2023 and business updates on February 15, 2024. A conference call will be held at 4:30 p.m. ET. Investors can access the live webcast at www.t2biosystems.com or dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 106354.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences earnings
-
News
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize
Rhea-AI Summary
T2 Biosystems, Inc. has been selected as a Phase 2 winner in the LymeX Diagnostics Prize, receiving $265,000 to advance the T2Lyme Panel for the detection of early Lyme disease. The T2Lyme Panel is designed to run on the FDA-cleared T2Dx Instrument and detect Borrelia burgdorferi, the bacteria that causes Lyme disease. The current diagnostic process for Lyme disease relies on the presence of antibodies and can only be used accurately four to six weeks after infection, making early diagnosis critical. The competition judging panel evaluated submissions based on official Phase 2 evaluation criteria, and at least $7 million in additional LymeX prizes are projected to be available in proposed future phases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
clinical trial
-
News
T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients
Rhea-AI Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) is participating in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients to determine the accuracy of multiple pathogen- and host-directed tests for the diagnosis of ventilator-associated pneumonia (VAP). The study aims to explore new approaches for diagnosing VAP and detecting antibiotic-resistant infections. The FDA-cleared T2Bacteria® Panel and the T2Resistance® Panel will be evaluated for the ability to rapidly detect infections in the blood currently missed by conventional methods. The study will be performed at Johns Hopkins Medicine laboratories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
News
T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing
Rhea-AI Summary
T2 Biosystems, a leader in rapid sepsis detection, submits FDA premarket notification for pediatric testing expansion of its FDA-cleared T2Candida Panel. The panel can detect sepsis-causing Candida pathogens directly from blood in just 3-5 hours, with a higher detection rate and faster species identification compared to blood culture. The submission marks an important milestone in the company's commitment to expanding the clinical utility of its sepsis test panels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.31%
Tags
none
-
News
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Rhea-AI Summary
T2 Biosystems, Inc. plans to participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The management will present on November 16, 2023, at 8:00am ET. A live and recorded webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
conferences
-
News
T2 Biosystems Regains Compliance with Nasdaq Listing Requirements
Rhea-AI Summary
T2 Biosystems, Inc. has regained compliance with the minimum bid price requirement of the Nasdaq Stock Market. The company maintained a minimum closing bid price of $1.00 or more for 10 consecutive trading days, with a closing bid price of $5.61 on October 26, 2023. T2 Biosystems will be subject to a Mandatory Panel Monitor for one year. If the company fails to comply with the Minimum Bid Price Requirement within this period, it may request a new hearing to avoid delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
News
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
Rhea-AI Summary
T2 Biosystems highlights new studies supporting the T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel at IDWeek conference. Data demonstrates speed, accuracy, and clinical benefits of T2Dx Instrument and sepsis panels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
clinical trial
-
News
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
Rhea-AI Summary
T2 Biosystems announces successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
none
-
News
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
Rhea-AI Summary
T2 Biosystems announces preliminary Q3 financial results, including a decrease in total revenue of 60% compared to the prior year period. The company received FDA clearance for the T2Biothreat Panel and strengthened its balance sheet by converting debt into equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4612.64%
Tags
earnings
News
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii
Rhea-AI Summary
T2 Biosystems submits 510(k) premarket notification to FDA to expand pathogen detection capabilities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4612.64%
Tags
none
Stock TTOO logo
T2 Biosystems Inc

Nasdaq:TTOO

TTOO Rankings

#5061 Ranked by Market Cap
#5524 Ranked by Stock Gains
N/A Ranked by Dividends

TTOO Stock Data

17.31M
4.66M
6.76%
19.28%
7.2%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www